Chronic Lymphocytic Leukemia Coverage from Every Angle
Advertisement
Advertisement

Published Medical Literature

Use of Ibrutinib in CLL: Update 5 Years After Approval
Venetoclax Therapy for Elderly Patients With Resistant CLL
Next-Generation Sequencing and Minimal Residual Disease in Patients With CLL
Five-Year Outcomes With Front-Line Ibrutinib in CLL
CLARITY Trial Update of Ibrutinib Plus Venetoclax in Resistant CLL
Does the Mode of Disease Progression Affect Outcomes in CLL?
Putting Clonal Evolution to Practical Use in Chronic Lymphocytic Leukemia
Survival Outcomes in CLL: Ibrutinib/Rituximab Versus Standard Chemoimmunotherapy
Phase III Trial Shows Venetoclax/Obinutuzumab Active in First-Line Treatment of CLL
Early Results With Cirmtuzumab/Ibrutinib Therapy for CLL
Immunotherapy Under Study in Resistant CLL: ZUMA-8 Trial
Phase II Trial of Acalabrutinib in Ibrutinib-Intolerant Patients With CLL
Gait Speed and Grip Strength: Predictors of Outcome in Hematologic Malignancies?
Newer Treatment Regimen for High-Risk and Older Patients With CLL
Considerations in Selecting Treatment in Resistant CLL
Addition of Ibrutinib to Initial Treatment for Younger Patients With CLL
Long-Term Study Confirms Benefit of Idelalisib in Relapsed CLL
Do Ibrutinib Dose Modifications Affect Long-Term Benefits in CLL?
Natural Killer Cell Function Activated by CD19-Targeted Molecule in CLL
Suboptimal Dosing of Ibrutinib in Patients With CLL
Minimal Residual Disease Status and Long-Term Survival in CLL
Potential of Nitrostyrene Compounds in CLL
Do Risks Outweigh Benefits for Use of Idelalisib Plus Ofatumumab in CLL?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.